Metsera, Inc. Common Stock Cash Flow Conversion Efficiency
Metsera, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Metsera, Inc. Common Stock (MTSR) has a cash flow conversion efficiency ratio of -0.131x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.96 Million) by net assets ($449.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Metsera, Inc. Common Stock (MTSR) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Metsera, Inc. Common Stock (2022–2024)
Cash flow conversion efficiency of Metsera, Inc. Common Stock from 2022 to 2024. This chart illustrates how Metsera, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Metsera, Inc. Common Stock stock quote for real-time trading data and today's change.
Metsera, Inc. Common Stock Cash Flow Conversion Ratio Explained
Metsera, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Metsera, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metsera, Inc. Common Stock ranked by their cash flow conversion efficiency. Review Metsera, Inc. Common Stock (MTSR) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nordstrom Inc
NYSE:JWN
|
0.786x |
|
Shandong Intco Medical Products Co Ltd
SHE:300677
|
0.023x |
|
Mobile World Investment Corp
VN:MWG
|
0.467x |
|
Solaris Energy Infrastructure, Inc.
NYSE:SEI
|
0.072x |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
0.019x |
|
Tidewater Inc
NYSE:TDW
|
0.062x |
|
VisEra Technologies Co. Ltd.
TW:6789
|
0.038x |
|
K.P.R. Mill Limited
NSE:KPRMILL
|
0.214x |
Annual Cash Flow Conversion Efficiency for Metsera, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Metsera, Inc. Common Stock from 2022 to 2024. Also see MTSR current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.35 Million | $-100.04 Million | -0.348x | +3.11% |
| 2023-12-31 | $98.50 Million | $-35.39 Million | -0.359x | -154.40% |
| 2022-12-31 | $-813.00K | $-537.00K | 0.661x | -- |
About Metsera, Inc. Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to re… Read more